Mike Arenberg : Appointed CFO of DURECT Corp.
Alumnus Mike Arenberg MBA ‘03 was appointed as DURECT Corporation’s new chief financial officer. He will be responsible for all financial and capital market activities at DURECT, including accounting, financial reporting, financial planning and analysis, and investor relations.
"I am excited to announce the promotion of Mike Arenberg as our new CFO," stated James E. Brown, President and CEO of DURECT, in a recent press release. "Mike has succeeded at each level of the organization as he has continually earned more responsibility over his long and distinguished tenure at DURECT. Mike is a talented and well-respected member of our senior management team with an excellent record of accomplishment that has prepared him well for this new role. On behalf of the entire company, I want to thank Matt for his contributions during his tenure at DURECT and am pleased that we'll have continuity through his consulting relationship as his duties are turned over to Mike."
DURECT is a biopharmaceutical company actively developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms.
Find the full press release here.